 |
Monica Heger tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb's In Sequence and Clinical Sequencing News. E-mail Monica Heger or follow her GenomeWeb Twitter accounts at @InSequence and @ClinSeqNews. |
Illumina Plans to Submit MiSeqDx Assays for Cystic Fibrosis to FDA this Year
November 01, 2012
Illumina Plans to Submit MiSeqDx Assays for Cystic Fibrosis to FDA this Year
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina Growing Clinical and Dx Business with Submission of MiSeqDx, Two CF Assays to FDA
January 9, 2013 / Clinical Sequencing News - Siemens Sees Opportunity for NGS in Clinical Dx as it Transitions HIV Assay to MiSeq
November 9, 2011 / Clinical Sequencing News - NIPT and Cancer Drive Illumina's Clinical Business in Q1 as it Looks to Launch Fetal Aneuploidy IVD
April 24, 2013 / Clinical Sequencing News - Illumina Focuses on Reproductive Health; May Modify MiSeq/HiSeq for Different Clinical Needs
January 30, 2013 / Clinical Sequencing News - Analysts Increase Valuations, Upgrade Illumina
January 4, 2013 / GenomeWeb Daily News